IFN-γ^−/−IL-17^−/− donor CD4⁺ T cells predominantly differentiated into Th2 and induced lung damage. (A) Intracellular cytokine profiles of splenic CD4⁺ T cells 7 days after HCT. Gated CD4⁺ T cells are shown in CD4 versus cytokines. A representative of 3 replicated experiments is shown. (B) Mean ± SE of serum IgE (n = 8) combined from 2 replicate experiments. (C) Mean ± SE of yield of eosinophil (CCR3⁺Gr-1⁺) in lungs 10 days after HCT (n = 4). (D) Intracellular cytokine profiles of CD4⁺ T cells among lung mononuclear cells 10 days after HCT. Gated CD4⁺ T cells were shown as IL-4/IL-5/IL-13 versus TNF-α or IL-10. Percentage of TNF-α⁺IL-4/IL-5/IL-13⁺ or IL-10⁺IL-4/IL-5/IL-13⁺ cells were calculated among total CD4⁺ T cells. A representative of 3 replicate experiments is shown. (E-F) Clinical scores and percent survival of recipients treated with TNFR-IgG or control IgG are shown. There were 12 mice in each group, combined from 3 replicate experiments. (G-H) H&E staining of lung tissue sections of recipients 15 days after HCT and mean ± SE of histopathology scores (n = 6). (I-J) BALB/c recipients given IFN-γ^−/−IL-17^−/− donor cells were treated with anti–IL-4 or rat IgG. H&E staining of lung tissue sections of recipients 15 days after HCT and mean ± SE of histopathology scores (n = 6). (K-L) WT or IL-4Rα^−/− BALB/c recipients were transplanted with IFN-γ^−/−IL-17^−/− donor cells. H&E staining of lung tissue sections of recipients 15 days after HCT and mean ± SE of histopathology scores (n = 6).